Morphle Labs Inc.

Morphle Labs Inc. , based in the US, provides innovative digital pathology solutions, focusing on automation and efficiency in laboratory environments through advanced robotic systems and imaging technologies. Founded in 2017 and headquartered in New York, US, Morphle Labs Inc. specializes in digital pathology.

The company has undergone a strategic focus on automating pathology processes. In November 2025, Morphle Labs raised USD 5 million in Series A funding from Inflexor Ventures, which will enhance their operational capabilities. The founder's prior entrepreneurial experience has contributed to the company’s strategic direction. Rohit Hiwale is founder and leading the firm as chief executive officer, as of 2025.

Morphle Labs Inc. specializes in advanced digital pathology solutions, with core offerings centered around robotic microtomes and whole slide imaging systems for high-throughput environments. Their flagship product, the ROBOTOME, automates data entry and can scan 40 slides per hour. Additionally, they offer the MorphoLens series of microscope slide scanners, catering to both high-volume laboratories and smaller research projects.

These products leverage optical character recognition and modern neural networks to improve efficiency in slide processing and data management, serving clients such as dermatopathologists, hospitals, and research institutions across North America and Europe. Morphle Labs generates revenue through the direct sale of its digital pathology products, primarily focusing on business-to-business transactions with healthcare providers and academic institutions. Revenue is derived from flagship offerings like the ROBOTOME and MorphoLens series, with transactions structured to meet client-specific needs. The company relies on equipment sales and service agreements for ongoing maintenance and support, ensuring reliable operation of their systems.

In November 2025, Morphle Labs Inc. raised USD 5 million in Series A funding led by Inflexor Ventures. The funding will be utilized to expand manufacturing capabilities, increase operational capacity, and support international intellectual property activities as well as regulatory compliance for medical device commercialization. The company aims to introduce new products and plans to enter additional international markets to further enhance its market presence.